Watchlist Price Alert

Crinetics Pharmaceuticals... (CRNX)

NASDAQ: CRNX · Real-Time Price · USD

30.70

-2.00 (-6.12%)

At close: May 09, 2025, 3:59 PM

30.68

-0.07%

After-hours: May 09, 2025, 04:26 PM EDT

-6.12% (1D)

Bid	29
Market Cap	2.87B
Revenue (ttm)	1.04M
Net Income (ttm)	-298.41M
EPS (ttm)	-3.69
PE Ratio (ttm)	-8.32
Forward PE	-6.99
Analyst	Buy

Ask	34.5
Volume	972,689
Avg. Volume (20D)	1,012,339
Open	33.28
Previous Close	32.70
Day's Range	30.68 - 34.24
52-Week Range	24.10 - 62.53
Beta	0.32

About CRNX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRNX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Crinetics Pharmaceuticals has released their quartely earnings on May 8, 2025:

Revenue of $361K exceeds estimates by $261K, with -43.59% YoY decline.

EPS of -1.04 misses estimates by -0.09, with -11.83% YoY decline.

Why Price Moved

5 months ago

+1.26%

Crinetics Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

9 months ago

-6.11%

Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.

News

2 days ago · zacks.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago.

1 month ago · seekingalpha.com

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over inje...

2 months ago · seekingalpha.com

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and...